Back to Search
Start Over
Successful renal denervation decreases the platelet activation status in hypertensive patients.
- Source :
-
Cardiovascular research [Cardiovasc Res] 2020 Jan 01; Vol. 116 (1), pp. 202-210. - Publication Year :
- 2020
-
Abstract
- Aims: To determine whether renal denervation (RDN) in hypertensive patients affects the platelet activation status.<br />Methods and Results: We investigated the effect of RDN on the platelet activation status in 41 hypertensive patients undergoing RDN. Ambulatory blood pressure (BP), plasma sympathetic neurotransmitter Neuropeptide Y, and platelet activation markers were measured at baseline, at 3 months, and 6 months after RDN. RDN significantly decreased BP at 3 months (150.6 ± 11.3/80.9 ± 11.4 mmHg to 144.7 ± 12.0/77.1 ± 11.1 mmHg; P < 0.01) and at 6 months (144.3 ± 13.8/78.3 ± 11.1 mmHg; P < 0.01). Plasma levels of the sympathetic neurotransmitter Neuropeptide Y, an indicator of sympathetic nerve activity, were significantly decreased at 3 months (0.29 ± 0.11 ng/mL to 0.23 ± 0.11 ng/mL; P < 0.0001) and at 6 months (0.22 ± 0.12 ng/mL; P < 0.001) after RDN. This was associated with a reduction in platelet membrane P-selectin expression (3 months, P < 0.05; 6 months, P < 0.05), soluble P-selectin (6 months, P < 0.05), circulating numbers of platelet-derived extracellular vesicles (EVs) (3 months, P < 0.001; 6 months, P < 0.01), and phosphatidylserine expressing EVs (3 months, P < 0.001; 6 months, P < 0.0001), indicative of a reduction in platelet activation status and procoagulant activity. Only patients who responded to RDN with a BP reduction showed inhibition of P-selectin expression at 3 months (P < 0.05) and 6 months (P < 0.05) as well as reduction of glycoprotein IIb/IIIa activation at 3 months (P < 0.05). Notably, 13 patients who took aspirin did not show significant reduction in platelet P-selectin expression following RDN.<br />Conclusion: Our results imply a connection between the sympathetic nervous system and the platelet activation status and provide a potential mechanistic explanation by which RDN can have favourable effects towards reducing cardiovascular complications.<br /> (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.)
- Subjects :
- Aged
Biomarkers blood
Blood Coagulation
Extracellular Vesicles metabolism
Female
Humans
Hypertension blood
Hypertension diagnosis
Hypertension physiopathology
Male
Middle Aged
Neuropeptide Y blood
P-Selectin blood
Phosphatidylserines blood
Platelet Glycoprotein GPIIb-IIIa Complex metabolism
Time Factors
Treatment Outcome
Blood Platelets metabolism
Blood Pressure
Catheter Ablation adverse effects
Hypertension surgery
Kidney blood supply
Platelet Activation
Renal Artery innervation
Sympathectomy adverse effects
Subjects
Details
- Language :
- English
- ISSN :
- 1755-3245
- Volume :
- 116
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Cardiovascular research
- Publication Type :
- Academic Journal
- Accession number :
- 30715163
- Full Text :
- https://doi.org/10.1093/cvr/cvz033